Скачать или смотреть Exercise Intervention Improves Colon Cancer Survival: Insights Beyond ASCO Plenary Data

Associate Professor of Oncology Bishal Gyawali, MD, PhD, FASCO, shares his key takeaways from the ASCO 2025 plenary session, focusing on practice-changing data and notable trial results. This discussion centers on a critical comparison between the highly compelling results of a structured exercise program for colon cancer survivors and the excitement surrounding new immunotherapy data.

This video dives into the CHALLENGE trial, which investigated a structured exercise program for high-risk stage II and stage III colon cancer patients who completed adjuvant chemotherapy. Bishal Gyawali discusses the statistically significant improvement in Disease-Free Survival (DFS) and Overall Survival (OS) achieved with this non-pharmacologic intervention. The analysis provides a provocative contrast between the low-cost, low-toxicity exercise program and the more complex and expensive immunotherapies, such as the Atezolizumab data from the ATOMIC trial presented at the plenary. Furthermore, the video includes a critical review of the SERENA-6 trial in metastatic breast cancer and the Matterhorn trial in esophageal cancers, scrutinizing their chosen endpoints and real-world applicability. This is a must-watch for clinicians considering the most practical and impactful strategies to improve patient outcomes in oncology.

00:00 - Introduction to the Exciting Data at ASCO 2025
00:15 - Exercise as an "Exercisezumab": Compelling Data
01:31 - The Challenging Implementation of Exercise
02:16 - The CHALLENGE Trial: Study Design and Significant Results
03:52 - Comparing Exercise to Immuno-Oncology (Atezolizumab/Atomic Trial)
05:55 - Cost-Effectiveness of Structured Exercise Programs
07:10 - Critiquing the SERENA-6 Trial in Metastatic Breast Cancer
08:08 - Limitations of the Matterhorn Trial with Durvalumab

#ASCO2025 #OncologyUpdates #ExerciseInOncology #CHALLENGETrial #CancerCare #BishalGyawali #Immunotherapy #ColonCancer #BreastCancer

https://www.medscape.com/viewarticle/...